sCD40L在炎症性肠病中的表达及临床意义

Efficacy of Salvianolate Injection in the treatment of experimental colitis in mice

AIM: To observe whether Salvianolate Injection has a therapeutic effect on colitis and to discuss the possible mechanisms involved.

METHODS: 50 Balb/c mice were randomly divided into a control group, a model group, and low-, medium-, and high-dose interventional groups. Colitis was induced by oral administration of 5% DSS for 7 d. Indices were determined 14 d after colitis induction.

RESULTS: Treatment with Salvianolate Injection could reduce colonic inflammation induced with DSS (P < 0.01). Immunohistochemistry analysis showed that treatment with different doses of Salvianolate Injection significantly reduced CD40/CD40L protein expression compared to the model group (CD40: 20.50 μm² ± 1.517 μm², 15.50 μm² ± 4.680 μm², 13.33 μm² ± 0.816 μm²vs 30.33 μm² ± 4.227 μm², all P < 0.01; CD40L: 23.17 μm² ± 2.714 μm², 15.50 μm² ± 2.739 μm², 14.17 μm² ± 4.262 μm²vs 27.83 μm² ± 3.710 μm², all P < 0.01). RT-PCR analysis showed that treatment with different doses of Salvianolate Injection significantly reduced CD40/CD40L mRNA expression compared to the model group (CD40: 1.20% ± 0.30%, 0.78% ± 0.26%, 0.41% ± 0.15% vs 1.78% ± 0.41%, all P < 0.01; CD40L: 2.59% ± 1.68%, 1.75% ± 0.64%, 1.11% ± 0.53% vs 3.54% ± 0.85%, all P < 0.01). The concentration of sCD40L in medium was decreased in the medium- and high-dose interventional groups compared to the model group (2.12 ng/mL ± 0.18 ng/mL, 1.96 ng/mL ± 0.12 ng/mL vs 5.62 ng/mL ± 0.36 ng/mL, P < 0.01).

CONCLUSION: Salvianolate Injection can exert a therapeutic effect on colitis in mice possibly by reducing sCD40L and thus restraining the CD40/CD40L pathway.